Search Results - "MEILIN LIAO"

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial by Reck, Martin, Dr, Kaiser, Rolf, MD, Mellemgaard, Anders, MD, Douillard, Jean-Yves, Prof, Orlov, Sergey, Prof, Krzakowski, Maciej, Prof, von Pawel, Joachim, MD, Gottfried, Maya, MD, Bondarenko, Igor, Prof, Liao, Meilin, Prof, Gann, Claudia-Nanette, MD, Barrueco, José, PhD, Gaschler-Markefski, Birgit, PhD, Novello, Silvia, Prof

“…Summary Background The phase 3 LUME-Lung 1 study assessed the efficacy and safety of docetaxel plus nintedanib as second-line therapy for non-small-cell lung…”
Get full text

Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non–Small-Cell Lung Cancer by PAZ-ARES, Luis G, BIESMA, Bonne, SYRIGOS, Kostas, LE MARIE, Etienne, GOTTFRIED, Maya, VANSTEENKISTE, Johan, ALBEROLA, Vincente, PHILLIP STRAUSS, Uwe, MONTEGRIFFO, Elaine, JIN ONG, Teng, SANTORO, Armando, HEIGENER, David, VON PAWEL, Joachim, EISEN, Timothy, BENNOUNA, Jaafar, LI ZHANG, MEILIN LIAO, YAN SUN, GANS, Steven

“…This trial evaluated the efficacy and safety of sorafenib plus gemcitabine/cisplatin in chemotherapy-naive patients with unresectable stage IIIB to IV…”
Get full text

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial by Wu, Yi-Long, Prof, Lee, Jin Soo, MD, Thongprasert, Sumitra, MD, Yu, Chong-Jen, Prof, Zhang, Li, Prof, Ladrera, Guia, MD, Srimuninnimit, Vichien, MD, Sriuranpong, Virote, MD, Sandoval-Tan, Jennifer, MD, Zhu, Yunzhong, Prof, Liao, Meilin, Prof, Zhou, Caicun, MD, Pan, Hongming, MD, Lee, Victor, FRCR, Chen, Yuh-Min, PhD, Sun, Yan, MD, Margono, Benjamin, PhD, Fuerte, Fatima, MD, Chang, Gee-Chen, MD, Seetalarom, Kasan, MD, Wang, Jie, Prof, Cheng, Ashley, MBBS, Syahruddin, Elisna, PhD, Qian, Xiaoping, MD, Ho, James, MD, Kurnianda, Johan, SPPD, Liu, Hsingjin Eugene, MD, Jin, Kate, MD, Truman, Matt, MSc, Bara, Ilze, MD, Mok, Tony, Prof

“…Summary Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly…”
Get full text

Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer by Mok, Tony S K, Wu, Yi-Long, Yu, Chong-Jen, Zhou, Caicun, Chen, Yuh-Min, Zhang, Li, Ignacio, Jorge, Liao, Meilin, Srimuninnimit, Vichien, Boyer, Michael J, Chua-Tan, Marina, Sriuranpong, Virote, Sudoyo, Aru W, Jin, Kate, Johnston, Michael, Chui, Winsome, Lee, Jin-Soo

“…This study investigated whether sequential administration of erlotinib and chemotherapy improves clinical outcomes versus chemotherapy alone in unselected,…”
Get full text

Genome-wide DNA Methylation Analysis Reveals GABBR2 as a Novel Epigenetic Target for EGFR 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment by Niu, Xiaomin, Liu, Fatao, Zhou, Yi, Zhou, Zhen, Zhou, Daizhan, Wang, Ting, Li, Ziming, Ye, Xiangyun, Yu, Yongfeng, Weng, Xiaoling, Zhang, Hong, Ye, Junyi, Liao, Meilin, Liu, Yun, Chen, Zhiwei, Lu, Shun

“…The past decade has witnessed the rapid development of personalized targeted therapies in lung cancer. It is still unclear whether epigenetic changes are…”
Get full text

The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines by Shen, Lan, Li, Ziming, Shen, Shengping, Niu, Xiaomin, Yu, Yongfeng, Li, Zonghai, Liao, Meilin, Chen, Zhiwei, Lu, Shun

“…Abstract Background Several studies implicated that lung cancer progression was governed by the interaction between estrogen receptor (ER) and epidermal growth…”
Get full text

First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009 by Soo, Ross A, Dr, Anderson, Benjamin O, Prof, Cho, Byoung Chul, MD, Yang, Chih-Hsin, Prof, Liao, Meilin, Prof, Lim, Wan-Teck, MB, Goldstraw, Peter, Prof, Mok, Tony S, Prof

“…Summary Non-small-cell lung cancer (NSCLC) is an increasing global challenge, especially in low-income countries. Most guidelines for the management of…”
Get full text

Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study by Huang, Yisheng, Zhang, Li, Shi, Yuankai, Ma, Shenglin, Liao, Meilin, Bai, Chunxue, Zhang, Qingyuan, Wang, Changli, Luo, Feng, Yu, Shiying, Qin, Shukui, Zhi, Xiuyi, Zhou, Caicun

“…This study is to analyze the data of Chinese subpopulation in the Tarceva Lung Cancer Survival Treatment Study (TRUST-China) which was a global Phase IV study…”
Get full text

Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: A large cohort retrospective study by Zhang, Li, Hou, Xue, Lu, Shun, Rao, Huilan, Hou, Jinghui, Luo, Rongzhen, Huang, He, Zhao, Hongyun, Jian, Hong, Chen, Zhiwei, Liao, Meilin, Wang, Xin

“…Abstract Background Bone is one of the most common sites of metastasis in patients with non-small-cell lung cancer (NSCLC). Over-expression of bone…”
Get full text

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy by Mok, Tony, Wu, Yi-Long, Lee, Jin Soo, Yu, Chong-Jen, Sriuranpong, Virote, Sandoval-Tan, Jennifer, Ladrera, Guia, Thongprasert, Sumitra, Srimuninnimit, Vichien, Liao, Meilin, Zhu, Yunzhong, Zhou, Caicun, Fuerte, Fatima, Margono, Benjamin, Wen, Wei, Tsai, Julie, Truman, Matt, Klughammer, Barbara, Shames, David S, Wu, Lin

“…Blood-based circulating-free (cf) tumor DNA may be an alternative to tissue-based EGFR mutation testing in NSCLC. This exploratory analysis compares matched…”
Get full text

A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China by Li, Longyun, Zhong, Wei, Liao, Meilin, Chen, Li, Han, Baohui, Guan, Zhongzhen, Yu, Shiying, Liu, Xuyi, Wu, Yilong, Jiang, Guoliang, Xu, Jianming, Chen, Jia, Tao, Min, Luo, Rongcheng, Li, Weimin, Xu, Nong, Zhao, Xiao, Wang, Mengzhao

“…The Expand Access Program (EAP) of Iressa(gefitinib, ZD1839) in China was initiated in 2001 with the aim of providing gefitinib to non-small cell lung cancer…”
Get full text

Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer by Liao, Meilin, Wang, Huimin, Lin, Zhenqiong, Feng, Jiuxian, Zhu, Dawei

“…Objective: An analysis of postoperative 1–5 year-survival rates related to vascular endothelial growth factor (VEGF) and vascular endothelial growth factor…”
Get full text

Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer by Novello, Silvia, Kaiser, Rolf, Mellemgaard, Anders, Douillard, Jean-Yves, Orlov, Sergey, Krzakowski, Maciej, von Pawel, Joachim, Gottfried, Maya, Bondarenko, Igor, Liao, Meilin, Barrueco, José, Gaschler-Markefski, Birgit, Griebsch, Ingolf, Palmer, Michael, Reck, Martin

“…Abstract Introduction The LUME-Lung 1 trial (NCT00805194; Study 1199.13) demonstrated a significant overall survival (OS) advantage for nintedanib plus…”
Get full text

Expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2014 version) by Sun, Yan, Guan, Zhongzhen, Liao, Meilin, Yu, Xin, Wang, Changli, Wang, Jie, Niu, Xiaohui, Shi, Yuankai, Zhi, Xiuyi, Liu, Yunpeng, Liu, Mengzhong, Zhang, Yiping, Yang, Yue, Shen, Jingnan, Chen, Gongyan, Zhou, Qinghua, Zhou, Caicun, Guo, Qisen, Tang, Lili, Duan, Jianchun, Liang, Jun, Zhang, Yingjian, Cheng, Ying

“…1 概述…”
Get full text

Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIA NSCLC patients with high VEGF expression by Chen, Zhiwei, Luo, Qingquan, Zhou, Zhen, Jian, Hong, Lu, Shun, Liao, Meilin

“…The aim of this study is to compare the therapeutic effect between endostar plus adjuvant chemotherapy and adjuvant chemotherapy alone in the patients with…”
Get full text

Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS) by Thongprasert, Sumitra, Duffield, Emma, Saijo, Nagahiro, Wu, Yi-Long, Yang, James Chih-Hsin, Chu, Da-Tong, Liao, Meilin, Chen, Yuh-Min, Kuo, Han-Pin, Negoro, Shunichi, Lam, Kwok Chi, Armour, Alison, Magill, Patrick, Fukuoka, Masahiro

“…Evaluation of health-related quality-of-life (HRQoL) and symptom improvement were preplanned secondary objectives for the overall population and posthoc…”
Get more information

Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules: A non-invasive biomarker for predicting malignancy and tumour invasiveness by Zhou, Qianjun, Geng, Qing, Wang, Lin, Huang, Jia, Liao, Meilin, Li, Yan, Ding, Zhengping, Yang, Shentu, Zhao, Hang, Shen, Qiang, Pan, Changqing, Lou, Jiatao, Lu, Shun, Chen, Chang, Luo, Qingquan

“…Non-invasive lung adenocarcinoma could benefit from limited resection, nonetheless, there is a lack of method to determine preoperative tumour invasiveness. We…”
Get full text

A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer by Lu, Shun, Li, Lu, Luo, Yi, Zhang, Li, Wu, Gang, Chen, Zhiwei, Huang, Cheng, Guo, Shuliang, Zhang, Yiping, Song, Xiangqun, Yu, Yongfeng, Zhou, Caicun, Li, Wei, Liao, Meilin, Li, Baolan, Xu, Liyan, Chen, Ping, Hu, Chunhong, Hu, Chengping

“…Based on promising efficacy in a single-arm study, a randomized phase II trial was designed to compare the efficacy and safety of adding rh-endostatin…”
Get more information

A survival comparison study of Chinese patients with primary lung adenocarcinoma harboring ALK rearrangements with crizotinib treatment detected by FISH, IHC, and RT-PCR by Liao, Meilin, Lu, Shun, Niu, Xiaomin, Chen, Zhiwei, Ye, Xiangyun, Li, Ziming, Yu, Yongfeng, Zhou, Zhen

“…Abstract only…”
Get full text

Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in China by Li, Ziming, Yu, Yongfeng, Lu, Jiade, Luo, Qinquan, Wu, Chunxiao, Liao, Meilin, Zheng, Ying, Ai, Xinghao, Gu, Lingping, Lu, Shun

“…The seventh edition of the tumor, node, metastasis Classification of Malignant Tumors is due to be published in 2009. The recommendations of International…”
Get more information